MiNK Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Advanced a phase II ARDS trial with early positive data and no major safety issues, expanded a paid access program to Brazil, and maintained financial discipline with a narrowed net loss. Enrollment continues in Ukraine and U.S. sites, with preliminary data expected in early 2027.
-
The meeting approved the election of directors and auditor, confirmed a quorum, and outlined a strategy focused on immune restoration across diseases. Key initiatives include advancing clinical trials in ARDS, expanding global access, and securing external funding for new therapies.
-
New clinical data show iNKT cell therapy's promise in cancer and ARDS, with a pivotal phase II trial underway and regulatory clearance in the US and Ukraine. Cash runway supports operations for 12 months, and partnerships expand platform reach.
Fiscal Year 2025
-
Advanced cell therapy platform showed durable survival in solid tumors and promising results in ARDS and GVHD, supported by increased cash reserves and non-dilutive funding. Key randomized trials and data readouts are expected in 2026.
-
Reported strong clinical progress with iNKT cell therapy showing durable responses in refractory cancers and advancing into GVHD and pulmonary disease trials. Financially, ended Q3 with $14.3M cash, extended runway through 2026, and leveraged a 700% equity price increase for capital efficiency.
-
Significant clinical milestones in oncology and immune diseases, reduced cash burn, and a strengthened balance sheet position the company for multiple value-creating milestones ahead. Fully funded trials and strategic partnerships are expected to accelerate program execution.
-
Q1 2025 saw major clinical progress in solid tumors and immune diseases, a 47% reduction in operating cash burn, and a net loss of $2.8M. Key programs in gastric and testicular cancer, ARDS, and GVHD advanced, with new partnerships and NIAID funding expected.
Fiscal Year 2024
-
2024 saw major clinical and operational progress, including reduced net loss and cash burn, strategic partnerships, and promising data in oncology and immunology. Key programs are advancing toward major milestones in 2025, with a cash runway through year-end.
-
Q3 2024 saw major progress in iNKT cell therapy programs, with reduced operating burn and strong early clinical signals in gastric cancer and GVHD. Cash use and net loss declined year-over-year, and key data updates are expected in early 2025.
-
The conference highlighted a robust pipeline of iNKT cell therapies, with lead program agenT-797 in phase II for gastric cancer and ARDS, and MiNK-215 advancing toward clinical trials. Early data show promising efficacy, scalable manufacturing, and strategic combinations to address high unmet needs.
-
Q2 2024 saw reduced cash burn and net loss, with strong progress in iNKT cell therapy programs for ARDS, gastric cancer, and GvHD. External funding and partnerships are key to advancing trials, with pivotal data and IND filings expected in late 2024 and 2025.